Clinical Trials Logo

Metastatic Bladder Cancer clinical trials

View clinical trials related to Metastatic Bladder Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06138561 Recruiting - Bladder Cancer Clinical Trials

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

Start date: March 5, 2024
Phase:
Study type: Observational

The goal of this study is to better understand how to best treat participants with advanced bladder cancer who may not be able to tolerate all of the chemotherapy drugs that have been shown to be effective. In this study, investigators are assessing the role of the survey, the Geriatric-8, and its ability to predict outcomes in older participants undergoing cancer treatments. Additionally, investigators are evaluating the differential impact of treatments on quality of life in an older and at risk population.

NCT ID: NCT06129084 Recruiting - Clinical trials for Metastatic Urothelial Carcinoma

A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing

Start date: January 11, 2021
Phase:
Study type: Observational

A new drug, erdafitinib, became available for some patients with bladder cancer that has spread to other organs. To qualify, patients must have specific genetic changes in their tumors. Currently, doctors use tumor tissue samples to check for these genetic changes, but these samples might not accurately reflect the current state of the patient's cancer. In this study, Investigators will test the patient's blood for these genetic changes in addition to the tumor tissue samples. It is thought that the blood test will give a more accurate result. Investigators hope this study will help to find out if more patients can benefit from erdafitinib than the ones identified by tissue testing only.

NCT ID: NCT05259319 Recruiting - Clinical trials for Metastatic Renal Cell Carcinoma

Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)

IMMUNOs-SBRT
Start date: December 5, 2022
Phase: Phase 1
Study type: Interventional

This study (phase I clinical trial and expansion cohorts) will evaluate safety and efficacy of combination of atezolizumab and tiragolumab, with concomitant or sequential SBRT for four oligometastatic cancer cohorts. This study will allow to developpe one or several randomized Phase II clinical trials for the more promising indications